Rilonacept (Arcalyst; Kiniksa Pharmaceuticals, London, UK) is an IL-1 blocker approved for treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) and of recurrent pericarditis. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.